Ozoralizumab is a humanized trivalent, bispecific NANOBODY® targeting TNFα with two anti-TNFα domains and an anti-HSA domain. It demonstrates strong anti-arthritis efficacy in human TNF transgenic mice, effective both at arthritis onset and during secondary failure of anti-TNFα IgG therapy. M.W 38.44 kDa.